Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof

The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.

Pharmaceutical Compositions for the Treatment of Pain

This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype α4β2 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by controlling neurotransmitter release in a subject.

FUEL CELL MODULE

The present invention provides a fuel cell, including a composite bipolar plate and gasket connecting bipolar plate. A sub-channel is assembled at a concave side of the gasket corresponding with bipolar plate. Main channels of gas running through both sides of the bipolar plate are arranged at separation positions between the bipolar plate and gas sub-channel. The main channels of gas and the gas sub-channel are connected through the channel. The airtight layer is assembled between the bipolar plate and gasket. With the airtight layer, the bipolar plate and gasket can be locked and fixed together steadily and tightly, so that the spaces of flow channels for different fuels can be definitely separated, without any leakage and mistaken mixture.

Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors

Compounds of formula (I) are novel P2X3and P2X2/P2X3antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

Clock data recovery circuit

A clock data recovery circuit. The clock data recovery circuit comprises a transmission line, a phase locked loop, a voltage controlled oscillator, a phase selector, and a D flip-flop. The transmission line receives an input signal. The phase locked loop receives the input signal via the transmission line and a reference clock and generates a first clock signal. The voltage controlled oscillator receives the input signal via the transmission line and a control voltage from an internal node of the phase locked loop, and generates a clock signal. The phase selector receives the input signal via the transmission line and the clock signal from the voltage controlled oscillator, and generates a clock output signal. The D flip-flop receives the input signal via the transmission line and the clock output signal, and generates a data output signal.

Bridgehead amine ring-fused indoles and indolines

The present application relates to indole and indoline derivatives of formula (I), formula (II), formula (III), or formula (IV) wherein a, R2, R3, h, k, m, n, L, Q, X, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions.

Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof

Compounds having formula (I) or formula (II) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A, N, X, Y, R1, R2 and R3 are as defined in the specification. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.

3,9-DIAZASPIRO[5,5]UNDECANE AMIDES AND UREAS AND METHODS OF USE THEREOF

Compounds of formula (I) are useful in treating conditions or disorders ameliorated by α4β2 postive allosteric modulators. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

6,7-disubstituted-4-aminopyridoÝ2,3-d¨pyrimidine compounds

CLOCK DATA RECOVERY CIRCUIT

A clock data recovery circuit. The clock data recovery circuit comprises a transmission line, a phase locked loop, a voltage controlled oscillator, a phase selector, and a D flip-flop. The transmission line receives an input signal. The phase locked loop receives the input signal via the transmission line and a reference clock and generates a first clock signal. The voltage controlled oscillator receives the input signal via the transmission line and a control voltage from an internal node of the phase locked loop, and generates a clock signal. The phase selector receives the input signal via the transmission line and the clock signal from the voltage controlled oscillator, and generates a clock output signal. The D flip-flop receives the input signal via the transmission line and the clock output signal, and generates a data output signal.

APPARATUSES AND METHODS FOR PROVIDING MULTI-STANDBY MODE OF WIRELESS COMMUNICATIONS USING SINGLE SUBSCRIBER IDENTITY CARD WITH MULTIPLE SUBSCRIBER NUMBERS

A communication device is provided with a processing unit. The processing unit reads a plurality of elementary files from a single subscriber identity card for each of a plurality of subscriber numbers when power-on, and registers to a network for each of the subscriber numbers according to the read elementary files. Also, the processing unit enables a multi-standby mode of wireless communications in response to successful registration to the network for at least two of the subscriber numbers. 1. A communication device , comprising:a processing unit reading a plurality of elementary files from a single subscriber identity card for each of a plurality of subscriber numbers when power-on, registering to a network for each of the subscriber numbers according to the read elementary files, and enabling a multi-standby mode of wireless communications in response to successful registration to the network for at least two of the subscriber numbers.2. The communication device of claim 1 , further comprising a storage unit storing the read elementary files.3. The communication device of claim 1 , wherein claim 1 , when at least one of the read elementary files is updated during the registration to the network claim 1 , the processing unit further writes the at least one updated elementary file back to the subscriber identity card.4. The communication device of claim 1 , wherein the reading of the elementary files further comprises:activating one subscriber identity module (SIM) instance in the subscriber identity card at a time for each of the subscriber numbers; andreading the elementary files of the activated SIM instance.5. The communication device of claim 4 , wherein the activating of the SIM instance further comprises:issuing a first command to the subscriber identity card for activating the SIM instance;receiving a response code corresponding to the first command from the subscriber identity card, wherein the response code indicates the communication device to fetch a ...

INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof

The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R 1 , R 2 and R 9 are as defined in the description.

Limiting amplifiers

A limiting amplifier with an input stage with dc offset cancellation, identical gain stages, an output buffer and a feedback filter. The input stage receives a differential input signal and outputs a first intermediate differential signal. The gain stages are cascaded to amplify the first intermediate differential signal and generate a second intermediate differential signal, amplified by the output buffer to produce an output signal. The feedback filter provides a dc offset voltage of the output signal to the input stage for the dc offset cancellation. The input stage comprises a resistor network coupled between a pair of input nodes and a power line and comprising a common resistor, a pair of load resistors and a shunt resistor. The load resistors share a common terminal connected to the common resistor that is connected to the power line. The shunt resistor has two terminals respectively connected to the load resistors.

Diagnosis and treatment of psoriatic arthritis

Methods and kits for diagnosing or predicting the risk of developing psoriatic arthritis in a subject in need of such diagnosis or risk prediction are provided, comprising measuring the expression level of one or more miRNAs disclosed herein in the sample of the subject, and compared the expression level of at least one of the miRNAs in the test sample with that of the psoriatic arthritis-free sample. Also provided are methods of treating psoriatic arthritis by reducing the expression level of at least one of the miRNAs disclosed herein.

CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

GLASS TREATMENT APPARATUS AND METHODS OF TREATING GLASS

A glass treatment apparatus comprise at least one upstream working device including a working wheel configured to rotate such that a working surface of the working wheel machines a surface portion of a glass sheet. The glass treatment apparatus further includes a downstream working device includes a working wheel comprising a cleaning wheel. In further examples, methods of treating glass comprise the step of machining a surface portion of a glass sheet with a working surface of a first rotating working wheel and the step of machining the surface portion of the glass sheet with a working surface of a second rotating working wheel comprising a cleaning wheel. 1. A glass treatment apparatus comprising:at least one upstream working device including a working wheel configured to rotate such that a working surface of the working wheel machines a surface portion of a glass sheet, and a shroud substantially circumscribing the working wheel; anda downstream working device positioned downstream from the at least one upstream working device, wherein the downstream working device includes a working wheel comprising a cleaning wheel configured to rotate such that a working surface of the cleaning wheel machines the surface portion of the glass sheet by cleaning the surface portion of the glass sheet to remove debris generated by machining the surface portion of the glass sheet with the at least one upstream working device.2. The glass treatment apparatus of claim 1 , wherein the shroud includes a slot configured to receive the surface portion of the glass sheet.3. The glass treatment apparatus of claim 1 , wherein the downstream working device further includes a shroud substantially circumscribing the cleaning wheel.4. The glass treatment apparatus of claim 3 , wherein the shroud includes a slot configured to receive the surface portion of the glass sheet.5. The glass treatment apparatus of claim 1 , wherein the working wheel of the at least one upstream working device comprises ...

(2S)-amino(phenyl)acetic acid and derivatives as alpha2delta voltage-gated calcium channel ligands

The present invention relates to a method for treating pain, reflex sympathetic dystrophy, spasticity, and bipolar disorder using ligands of the alpha₂delta voltage-gated calcium channel, wherein the ligand comprises (2s)-aminophenyl acetic acid and derivatives.

FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS

Compounds of formula (I) are novel P2X 3 and P2X 2 /P2X 3 containing receptor antagonists and are useful in treating pain, urinary incontinence, and bladder overactivity.

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Frequency Synthesizer

A frequency synthesizer. The frequency synthesizer comprises a harmonic locked phase/frequency detector, a low pass filter, a voltage controlled oscillator, and a frequency divider. The harmonic locked phase/frequency detector receives a reference signal and a divided signal. The low pass filter is coupled to the harmonic locked phase/frequency detector. The voltage controlled oscillator is coupled to the low pass filter and provides an output signal. The frequency divider is coupled between the voltage controlled oscillator and the harmonic locked phase/frequency detector. Frequency of the divided signal is a harmonic frequency of the reference signal.

SIGNAL AMPLIFICATION CIRCUITS FOR RECEIVING/TRANSMITTING SIGNALS ACCORDING TO INPUT SIGNAL

One exemplary signal amplification circuit used for processing an input signal includes an input stage, a plurality of output stages, and a selecting stage. The input stage has an input node for receiving the input signal and an output node for outputting an intermediate signal. The output stages are coupled to a plurality of output ports of the signal amplification circuit, respectively. Each of the output stages generates a corresponding processed signal to a corresponding output port according to a gain and a signal derived from the intermediate signal of the input stage when enabled. The selecting stage is arranged for selectively coupling the output node of the input stage to at least one of the output stages.

Separator for lithium cells having porous and cured layers on a non-woven support

In an embodiment of the disclosure, a separator utilized in a lithium battery is provided. The separator includes a non-woven polyester support, a porous layer of polyvinylidene fluoride (PVDF) or its derivatives formed on the non-woven polyester support, a layer of UV-curing or thermal-curing polymers formed on top of the porous layer of polyvinylidene fluoride (PVDF) or its derivatives.

FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Loudspeaker apparatus

The disclosure provides a loudspeaker apparatus and a method of driving the acoustic transducers by predicting and compensating a physical phenomenon of acoustic pressure changes within an enclosure caused by at least one of the acoustic transducers. The loudspeaker apparatus includes an enclosure having an inner space, a first acoustic transducer, a second acoustic transducer, and a controller. The first and second acoustic transducers are mounted on the enclosure and share the same inner space of the enclosure, such as sound bar and the likes. For the operation of the loudspeaker apparatus, the controller applies an algorithm or mathematical model (e.g., transfer function) to an audio signal received from an external source, so that the sound respectively outputted by the first and second acoustic transducers sharing the same inner space may be compensated as if the first and second acoustic transducers are individually mounted on its own enclosure.

(2S)-amino(phenyl)acetic acid and derivatives as alpha2delta voltage-gated calcium channel ligands

The present invention relates to a method of treating disorders associated with the α2δ voltage-gated calcium channel ligand, comprising the administration of compounds of formula (I), or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.

LIMITING AMPLIFIERS

A limiting amplifier with an input stage with dc offset cancellation, identical gain stages, an output buffer and a feedback filter. The input stage receives a differential input signal and outputs a first intermediate differential signal. The gain stages are cascaded to amplify the first intermediate differential signal and generate a second intermediate differential signal, amplified by the output buffer to produce an output signal. The feedback filter provides a dc offset voltage of the output signal to the input stage for the dc offset cancellation. The input stage comprises a resistor network coupled between a pair of input nodes and a power line and comprising a common resistor, a pair of load resistors and a shunt resistor. The load resistors share a common terminal connected to the common resistor that is connected to the power line. The shunt resistor has two terminals respectively connected to the load resistors.

Biaryl substituted azabicyclic alkane derivatives

The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Pharmaceutical compositions and their methods of use

The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

Signal amplification circuits for receiving/transmitting signals according to input signal

An exemplary signal amplification circuit includes an input stage, a plurality of output stages and a selecting stage. The input stage has an input node for receiving an input signal and an output node for outputting an intermediate signal. The output stages are coupled to a plurality of output ports of the signal amplification circuit, respectively. Each output stage generates a corresponding processed signal to a corresponding output port according to a gain and the intermediate signal when enabled. The selecting stage selectively couples the output node of the input stage to at least one of the output stages. The signal amplification circuit outputs a first number of processed signal(s) when operated under a first operational mode, and outputs a second number of processed signal(s) when operated under a second operational mode.

SEALING STRUCTURE FOR A BIPOLAR PLATE OF A FUEL CELL

The present invention provides a sealing structure for a bipolar plate of a fuel cell. The sealing structure includes a plurality of bipolar plates and a gas guidance and reaction layer. A gas channel is placed laterally onto the bipolar plate corresponding to the gas guidance and reaction layer. A gasket is located between a bipolar plate and the gas guidance and reaction layer. A permeable portion is formed on the gasket corresponding to the gas channel. A concave surface is placed laterally on the bipolar plate corresponding to the gas guidance and reaction layer for mating with the gasket. When the bipolar plate, gas guidance and reaction layer and gasket are fastened, the deformation amount of the gasket is accurately controlled through the height limitation of the concave surface.

Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR

Compounds of formula (I) 9. The compound of wherein{'sub': 5', 'A', 'A, 'Ris —O—P(O)(OR)(OR).'}10. The compound of wherein{'sub': 5', 'A', 'A, 'Ris —P(O)(OR)(OR).'}11. The compound of wherein{'sub': 5', 'A, 'Ris —OR.'}12. The compound of wherein{'sub': 5', 'A, 'Ris —OC(O)(R).'}13. The compound of wherein{'sub': '5', 'Ris heterocycle.'}14. The compound of wherein{'sub': 5', 'A, 'Ris —C(O)OR.'}15. The compound of wherein{'sub': 5', 'A', 'B', 'A', 'A', 'B', 'B', '2, 'Ris selected from the group consisting of —C(O)R, —N(R)C(O)OR, —NRR, and —C(O)N(R).'}27. The compound of wherein{'sub': 5', 'A', 'A, 'Ris —O—P(O)(OR)(OR).'}28. The compound of wherein{'sub': 5', 'A', 'A, 'Ris —P(O)(OR)(OR).'}29. The compound of wherein{'sub': 5', 'A, 'Ris —OR.'}30. The compound of wherein{'sub': 5', 'A, 'Ris —OC(O)(R).'}31. The compound of wherein{'sub': '5', 'Ris heterocycle.'}32. The compound of wherein{'sub': 5', 'A, 'Ris —C(O)OR,'}33. The compound of wherein{'sub': 5', 'A', 'B', 'A', 'A', 'B', 'B', '2, 'Ris selected from the group consisting of —C(O)R, —N(R)C(O)OR, —NRR, and —C(O)N(R).'}37. The compound selected from the group consisting ofN-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-morphol in-4-ylethyl)-1H-indazol-4-yl]urea;2-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-oxoethyl acetate;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-yl-N-(2-morpholin-4-ylethyl)urea;N-{1-[(benzyloxy)acetyl]-1H-indazol-4-yl}-N′-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(methoxyacetyl)-1H-indazol-4-yl]urea;4-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl1-4-oxobutanoic acid;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′t1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea trifluoroacetic acid salt;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-(1-glycoloyl-1H-indazol-4-yl)urea;N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′- ...

PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE

The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an 42 positive allosteric modulator, a method of using the same, and a related article of manufacture.

Amides that inhibit vanilloid receptor subtype 1 (VR1)

The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compound of formula (I) are novel VR1 antagonist that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Driving system for driving a scan-type display

A driving system includes a scan driving device. The scan driving device includes a configuration register, a counter, multiple comparators and a driver. The configuration register generates a counting parameter and multiple scan order parameters based on a serial input signal and a clock signal. The counter generates a counting value based on the clock signal, an enable signal and the counting parameter. Each comparator compares the counting value with a respective one of the scan order parameters to generate a comparison result. The driver generates multiple scan driving signals for driving a scan-type display based on the clock signal, on the enable signal and on the comparison results respectively generated by the comparators.

AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF

The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

Pharmaceutical compositions for the treatment of pain

This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype 42 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by controlling neurotransmitter release in a subject.

AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF

The invention relates to novel amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1—X5, R5—R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Selective laser sintering composition and selective laser sintering 3D printing method employing the same

A selective laser sintering composition and a selective laser sintering 3D printing method employing the same are provided. The selective laser sintering composition includes a nanoscale inorganic powder and a thermoplastic vulcanizate powder. The temperature difference (ΔT) between the onset temperature for melting the thermoplastic vulcanizate powder and the onset temperature at which the thermoplastic crystallizes vulcanizate powder is greater than or equal to 10° C. The thermoplastic vulcanizate powder includes a thermoplastic and a crosslinked polymer. The temperature difference (ΔT) between the onset temperature for melting the thermoplastic and the onset temperature at which the thermoplastic crystallizes is greater than or equal to 10° C. , and the weight ratio of the thermoplastic to the crosslinked polymer is from 1:1 to 1:4.

Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF

The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X₁, X₂, X₃, X₄, X₅, R₅, R₆, R₇, R_8a, R_8b, R₉, Z₁, Z₂ and L are as defined in the description.

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. 2. The compound according to claim 1 , wherein{'sub': '1', 'A is Ar.'}4. The compound according to claim 3 , wherein{'sub': '1', 'Lis —O—.'}5. The compound according to claim 3 , wherein{'sub': 1', 'a, 'Lis —NR—.'}6. The compound according to claim 1 , wherein{'sub': 2', '2', '3, 'A is —Ar-L-Ar.'}9. The compound according to claim 6 , wherein{'sub': 1', 'a, 'Lis —NR—; and'}{'sub': '2', 'Lis a bond.'}10. The compound according to claim 6 , wherein{'sub': '1', 'Lis —O—; and'}{'sub': '2', 'Lis a bond.'}11. The compound according to claim 1 , wherein{'sub': 4', '3', '5, 'A is —Ar-L-Ar.'}13. A compound of claim 1 , wherein the compound is{'sup': '3,7', '(4s)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-bromopyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[5-(1H-indol-5-yl)pyridin-2-yloxy]-1- ...

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. 2. The compound according to claim 1 , wherein{'sub': '1', 'A is Ar.'}4. The compound according to claim 3 , wherein{'sub': '1', 'Lis —O—.'}5. The compound according to claim 3 , wherein{'sub': 1', 'a, 'Lis —NR—.'}6. The compound according to claim 1 , wherein{'sub': 2', '2', '3, 'A is —Ar-L-Ar.'}9. The compound according to claim 6 , wherein{'sub': 1', 'a, 'Lis —NR—; and'}{'sub': '2', 'Lis a bond.'}10. The compound according to claim 6 , wherein{'sub': '1', 'Lis —O—; and'}{'sub': '2', 'Lis a bond.'}11. The compound according to claim 1 , wherein{'sub': 4', '3', '5, 'A is —Ar-L-Ar.'}13. A compound of claim 1 , wherein the compound is{'sup': '3,7', '(4s)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-bromopyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[5-(1H-indol-5-yl)pyridin-2-yloxy]-1- ...

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

METHOD TO MANIPULATE BRITTLE MATERIAL SHEET COMPOUND SHAPE

A method for manipulating a glass sheet compound shape during a severing operation including, for example, positioning a scoring device against the first side of the central portion of the glass sheet, and temporarily bending an extended portion of the glass sheet located between the scoring device and a selected one of the edge portions from a first orientation to a severing orientation by applying a force to the extended portion of the glass sheet. In one example, the force can be applied to achieve a predetermined surface stress in the glass sheet. The method can further include forming a score line along the first side of the central portion of the glass sheet while the force is being applied to the extended portion, and breaking away the selected one of the edge portions from the glass sheet along the score line. 1. A method to manipulate a glass sheet compound shape during a severing operation , comprising:positioning a scoring device against the first side of the central portion of the glass sheet, the glass sheet having a pair of opposed edge portions and a central portion laterally spanning between the opposed edge portions, and the central portion having a first side facing a first direction and a second side facing a second direction opposite the first direction;temporarily bending an extended portion of the glass sheet located between the scoring device and a selected one of the edge portions from a first orientation to a severing orientation by applying a force to the extended portion of the glass sheet;forming a score line along the first side of the central portion of the glass sheet while the force is being applied to the extended portion of the glass sheet; andbreaking away the selected one of the edge portions from the glass sheet along the score line.2. The method of claim 1 , wherein the extended portion of the glass sheet is temporarily bent in a direction toward the first side of the glass sheet.3. The method of claim 1 , wherein the force is ...

SEPARATORS UTILIZED IN LITHIUM BATTERIES

In an embodiment of the disclosure, a separator utilized in a lithium battery is provided. The separator includes a non-woven polyester support, a porous layer of polyvinylidene fluoride (PVDF) or its derivatives formed on the non-woven polyester support, a layer of UV-curing or thermal-curing polymers formed on top of the porous layer of polyvinylidene fluoride (PVDF) or its derivatives.

Spirocyclic azaadamantane derivatives and methods of use

The invention relates to compounds that are spirocyclic azaadamantane derivatives derivatives, particularly spirocyclic azaadamantanyl ether or amine derivatives, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Novel Isoxazoles and Methods of Use Thereof

The invention relates to isoxazole derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.

Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors

Compounds of formula (I)are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof

The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.

Indole and indoline derivatives and methods of use thereof

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R 1 , R 2 , R 3 , R 4 , R 5 , U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Diplexer and transceiver thereof

A diplexer, for coupling a first radio frequency (RF) signal corresponding to a first carrier frequency and a second RF signal corresponding to a second carrier frequency is disclosed. The diplexer includes a first port arranged to couple the first RF signal; a second port arranged to couple the second RF signal; a third port capable of connecting an antenna; a first impedance unit coupled to the first port and the third port; and a second impedance unit coupled to the second port and the third port; wherein the first port, the second port and the third port are coupled to a direct current (DC) ground; wherein the first impedance unit is arranged to provide an first open-circuit impedance against the second RF signal, and the second impedance unit is arranged to provide a second open-circuit impedance against the first RF signal.

Azaadamantane derivatives and methods of use

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Adapter for antenna on a mobile phone

An adapter for antenna on a mobile phone basically is a main body associated with an adapting tube and a cover. A receiving recession is provided between the main body and the cover for containing a wave eliminating plate. The adapting tube is used for fitting with the antenna. The main body has a plurality of through holes for being passed by the rubber forming the adapting tube. The rubber overflowed from each through hole is associated with each other and constitutes a fixing part such that the adapting tube is integrated with the main body. The adapting tube is made of highly elastic and non-brittle rubber and has features such as flexible, free from aging, and durable. Therefore, the adapter is possible to sleeve with any size of antenna on a mobile phone firmly without a phenomenon of being loosened due to elastic fatigue and being damaged due to brittleness after using a period of time.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES

The invention relates biaryl substituted diazabicycloalkanes, and more particularly bicycloheteroaryl substituted fused diazabicycloalkane derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.

3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof

Compounds of formula (I) are useful in treating conditions or disorders ameliorated by 42 positive allosteric modulators. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors

Compounds of formula (I)are novel P2X3 and P2X2/P2X3 containing receptor antagonists and are useful in treating pain, urinary incontinence, and bladder overactivity.

Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors

Compounds of formula (I) are novel P2X 3 and P2X 2 /P2X 3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

Methods for Treating Pain

The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an 7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonictc and have formula (I) 2. The compound according to wherein{'sub': 1', 'b, 'Yis —N(R)—;'}{'sub': '2', 'Yis O; and'}{'sub': 3', 'c, 'Yis —N(R)—.'}3. The compound according to claim 2 , wherein Lis cycloalkyl wherein the cycloalkyl is cyclopentyl or cyclohexyl.4. The compound of claim 3 , wherein Aris phenyl.5. The compound according to claim 4 , wherein the phenyl is unsubstituted or substituted with 1 claim 4 , 2 claim 4 , 3 claim 4 , 4 claim 4 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 4 , alkyl claim 4 , arylalkyl claim 4 , halogen claim 4 , haloalkyl claim 4 , or RRN— wherein Rand Rare each independently hydrogen claim 4 , alkyl claim 4 , or haloalkyl.6. The compound according to claim 5 , wherein{'sub': '1', 'Ris hydroxy; and'}{'sub': 2', '3', '4', '5, 'R, R, R, and Rare hydrogen.'}7. The compound according to claim 2 , wherein Lis a bond.8. The compound according to claim 7 , wherein Aris a monocyclic heterocycle fused to a phenyl.9. The compound of claim 8 , wherein{'sub': '1', 'Ris hydroxy;'}{'sub': '2', 'Ris hydrogen, and'}{'sub': '1', 'Aris 3,4-dihydro-2H-chromen-3-yl.'}10. The compound according to wherein Aris optionally substituted with 1 claim 9 , 2 claim 9 , 3 claim 9 , 4 claim 9 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 9 , alkyl claim 9 , arylalkyl claim 9 , halogen claim 9 , haloalkyl claim 9 , or RRN— wherein Rand Rare each independently hydrogen claim 9 , alkyl claim 9 , or haloalkyl.11. The compound according to claim 8 , wherein{'sub': '1', 'Ris hydroxy;'}{'sub': '2', 'Ris hydrogen; and'}{'sub': '1', 'Aris 3,4-dihydro-2H-chromen-4-yl.'}12. The compound according to wherein Aris optionally substituted with 1 claim 11 , 2 claim 11 , 3 claim 11 , 4 claim 11 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 11 , alkyl claim 11 , arylalkyl claim 11 , halogen claim 11 , ...

SIGNAL AMPLIFICATION CIRCUITS FOR RECEIVING/TRANSMITTING SIGNALS ACCORDING TO INPUT SIGNAL

An exemplary signal amplification circuit includes an input stage, a plurality of output stages and a selecting stage. The input stage has an input node for receiving an input signal and an output node for outputting an intermediate signal. The output stages are coupled to a plurality of output ports of the signal amplification circuit, respectively. Each output stage generates a corresponding processed signal to a corresponding output port according to a gain and the intermediate signal when enabled. The selecting stage selectively couples the output node of the input stage to at least one of the output stages. The signal amplification circuit outputs a first number of processed signal(s) when operated under a first operational mode, and outputs a second number of processed signal(s) when operated under a second operational mode. 1. A signal amplification circuit for processing an input signal , comprising:an input stage, having an input node for receiving the input signal and an output node for outputting an intermediate signal;a plurality of output stages, coupled to a plurality of output ports of the signal amplification circuit, respectively, wherein each of the output stages generates a corresponding processed signal to a corresponding output port according to a gain and the intermediate signal when enabled; anda selecting stage, arranged for selectively coupling the output node of the input stage to at least one of the output stages;wherein the signal amplification circuit outputs a first number of processed signal(s) in response to the input signal when operated under a first operational mode, and the signal amplification circuit outputs a second number of processed signal(s) in response to the input signal when operated under a second operational mode, where the second number is different from the first number.2. The signal amplification circuit of claim 1 , wherein the first operational mode is a shared mode; the second operational mode is a combo mode; ...

AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF

The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES

The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

LIMITING AMPLIFIERS

A limiting amplifier with an input stage with dc offset cancellation, identical gain stages, an output buffer and a feedback filter. The input stage receives a differential input signal and outputs a first intermediate differential signal. The gain stages are cascaded to amplify the first intermediate differential signal and generate a second intermediate differential signal, amplified by the output buffer to produce an output signal. The feedback filter provides a dc offset voltage of the output signal to the input stage for the dc offset cancellation. The input stage comprises a resistor network coupled between a pair of input nodes and a power line and comprising a common resistor, a pair of load resistors and a shunt resistor. The load resistors share a common terminal connected to the common resistor that is connected to the power line. The shunt resistor has two terminals respectively connected to the load resistors.

BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.

Apparatuses and methods for providing multi-standby mode of wireless communications using single subscriber identity card with multiple subscriber numbers

A communication device is provided with a processing unit. The processing unit reads a plurality of elementary files from a single subscriber identity card for each of a plurality of subscriber numbers when power-on, and registers to a network for each of the subscriber numbers according to the read elementary files. Also, the processing unit enables a multi-standby mode of wireless communications in response to successful registration to the network for at least two of the subscriber numbers.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I) that useful in treating pain.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

1,2,4 oxadiazole compounds and methods of use thereof

The invention relates to 1,2,4 oxadiazole compounds and analogs thereof, represented by formula (II), and compositions and methods of use thereof.

TRPV1 Antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, 2. The compound of of formula (I) or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , prodrug claim 1 , or a combination thereof wherein{'sup': 1', '2', '3', '4', 'a, 'one of X, X, X, and Xis C, and the others are C(R); and'}{'sup': 'a', 'each Ris the same or different, and are each independently hydrogen or halogen.'}3. The compound of of formula (I) or a pharmaceutically acceptable salt claim 2 , solvate claim 2 , prodrug claim 2 , or a combination thereof wherein{'sup': 5', '6', '3', '4', '5', '6, 'X-Xis C(RR)C(RR); and'}{'sup': '2', 'Gis optionally substituted aryl.'}5. The compound of or a pharmaceutically acceptable salt claim 4 , solvate claim 4 , prodrug claim 4 , or a combination thereof claim 4 , wherein X claim 4 , X claim 4 , and Xare C(R).6. The compound of or a pharmaceutically acceptable salt claim 5 , solvate claim 5 , prodrug claim 5 , or a combination thereof claim 5 , wherein{'sup': '3J', 'J is CR;'}{'sup': '3k', 'K is N or CR;'}{'sup': '3L', 'L is NR; and'}{'img': {'@id': 'CUSTOM-CHARACTER-00099', '@he': '2.46mm', '@wi': '7.79mm', '@file': 'US20120245163A1-20120927-P00001.TIF', '@alt': 'custom-character', '@img-content': 'character', '@img-format': 'tif'}, 'is a double bond.'}7. The compound of or a pharmaceutically acceptable salt claim 6 , solvate claim 6 , prodrug claim 6 , or a combination thereof claim 6 , whereinK is N; and{'sup': 5', '6', '3a', '3b', '3', '4', '5', '6', '9', '10', '11', '12', '13', '14, 'X-Xis CRR, C(RR)C(RR), or C(RR)C(RR)C(RR).'}8. The compound of or a pharmaceutically acceptable salt claim 6 , solvate claim 6 , prodrug claim 6 , or a combination thereof claim 6 , whereinK is N;{'sup': 5', '6', '3', '4', '5', '6, 'X-Xis C(RR)C(RR); and'}{'sup': '2', 'Gis aryl, heteroaryl, or cycloalkyl, each of which is optionally substituted.'}9. The compound of or a pharmaceutically acceptable salt claim ...

SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are spirocyclic azaadamantane derivatives derivatives, particularly spirocyclic azaadamantanyl ether or amine derivatives, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

TRPV1 antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof

The present invention discloses fused thienopyridyl compounds of general formula (I) wherein X1-X6, R5-R7, Z1 and L are as defined in the description. The resent invention also discloses a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals, and pharmaceutical compositions including those compounds.

MULTI-LAYERED POROUS FILM AND METHOD FOR PREPARING THE SAME

A multi-layered porous film is provided. The film includes a first porous layer having a first plurality of pores each with an aspect ratio of from 1:2 to 1:5; a second porous layer having a second plurality of pores each with an aspect ratio of from 1:2 to 1:5; and a thermal-resistance layer having a third plurality of pores, wherein the thermal-resistance layer is disposed between the first porous layer and the second porous layer, and has 50 wt % to 80 wt % of inorganic particles. A method for preparing the above multi-layered porous film is further provided. 1. A multi-layered porous film , comprising:a first porous layer having a first plurality of pores each with an aspect ratio of 1:2 to 1:5;a second porous layer having a second plurality of pores each with an aspect ratio of 1:2 to 1:5; anda thermal-resistance layer having a third plurality of pores, wherein the thermal-resistance layer is disposed between the first porous layer and the second porous layer, and the thermal-resistance layer comprises 50 wt % to 80 wt % of inorganic particles.2. The multi-layered porous film of claim 1 , wherein each of the first porous layer claim 1 , the second porous layer claim 1 , and the thermal-resistance layer comprises a polyolefin resin.3. The multi-layered porous film of claim 2 , wherein the polyolefin resin comprises one selected from the group consisting of polyethylene claim 2 , polypropylene and a combination thereof.4. The multi-layered porous film of claim 3 , wherein the polyethylene has a weight average molecular weight of from 10000 to 13000.5. The multi-layered porous film of claim 3 , wherein the polypropylene has a weight average molecular weight of from 55000 to 70000.6. The multi-layered porous film of claim 2 , wherein the polyolefin resin of the first porous layer and the polyolefin resin of the second porous layer each comprise polyethylene.7. The multi-layered porous film of claim 2 , wherein the polyolefin resin of the thermal-resistance layer ...

SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are spirocyclic azaadamantane derivatives, particularly spirocyclic azaadamantanyl ether or amine derivatives, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES

The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The isoquinoline compounds of formula (I) are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The "R", "Z" and "L" variables are defined in the disclosure and the "X" variables are defined as follows: X₁ is CR₁; X₂ is selected from the group consisting of N and CR₂; X₃ is selected from the group consisting of N and CR₃; X₄ is CR₄; and X₅ is selected from the group consisting of N and C.

Amide derivatives as positive allosteric modulators and methods of use thereof

The invention relates to novel amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

Methods for treating pain

The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an 7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt.

METHOD FOR DETERMINING A RISK, FOR A SUBJECT, OF SUFFERING FROM ATOPIC DERMATITIS OR SEVERITY OF ATOPIC DERMATITIS FOR A SUBJECT SUFFERING FROM ATOPIC DERMATITIS AND METHOD FOR USING A SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS A BIOMARKER FOR DETERMINING THE DEVELOPMENT OR SEVERITY OF ATOPIC DERMATITIS

The invention provides a method for determining a risk, for a subject, of suffering from atopic dermatitis, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining the risk, for the subject, of suffering from atopic dermatitis, wherein the presence of a C allele or genotype CC of the single-nucleotide polymorphism rs12313273 (C/T) indicates that the subject is at increased risk for suffering from atopic dermatitis.

LOUDSPEAKER APPARATUS

The disclosure provides a loudspeaker apparatus and a method of driving the acoustic transducers by predicting and compensating a physical phenomenon of acoustic pressure changes within an enclosure caused by at least one of the acoustic transducers. The loudspeaker apparatus includes an enclosure having an inner space, a first acoustic transducer, a second acoustic transducer, and a controller. The first and second acoustic transducers are mounted on the enclosure and share the same inner space of the enclosure, such as sound bar and the likes. For the operation of the loudspeaker apparatus, the controller applies an algorithm or mathematical model (e.g., transfer function) to an audio signal received from an external source, so that the sound respectively outputted by the first and second acoustic transducers sharing the same inner space may be compensated as if the first and second acoustic transducers are individually mounted on its own enclosure. 1. A loudspeaker apparatus , comprising:an enclosure, having an inner space;a first acoustic transducer, mounted to the enclosure;a second acoustic transducer, mounted to the enclosure and sharing the same inner space as the first acoustic transducer; receiving a first audio signal for driving the first acoustic transducer;', 'filtering the first audio signal; and', 'driving the second acoustic transducer based at least on the filtered first audio signal., 'a controller, coupled to the first and second acoustic transducers, and configured for2. The loudspeaker apparatus of claim 1 , wherein the controller is further configured for:receiving a second audio signal for driving the second acoustic transducer;combining the second audio signal and the filtered first audio signal to generate a second driving signal; anddriving the second acoustic transducer based at least on the second driving signal.3. The loudspeaker apparatus of claim 1 , wherein the first audio signal is filtered by applying a first transfer function.4. ...

LIMITING AMPLIFIERS

A limiting amplifier with an input stage with dc offset cancellation, identical gain stages, an output buffer and a feedback filter. The input stage receives a differential input signal and outputs a first intermediate differential signal. The gain stages are cascaded to amplify the first intermediate differential signal and generate a second intermediate differential signal, amplified by the output buffer to produce an output signal. The feedback filter provides a dc offset voltage of the output signal to the input stage for the dc offset cancellation. The input stage comprises a resistor network coupled between a pair of input nodes and a power line and comprising a common resistor, a pair of load resistors and a shunt resistor. The load resistors share a common terminal connected to the common resistor that is connected to the power line. The shunt resistor has two terminals respectively connected to the load resistors.

Limiting amplifiers

A limiting amplifier with an input stage with dc offset cancellation, identical gain stages, an output buffer and a feedback filter. The input stage receives a differential input signal and outputs a first intermediate differential signal. The gain stages are cascaded to amplify the first intermediate differential signal and generate a second intermediate differential signal, amplified by the output buffer to produce an output signal. The feedback filter provides a dc offset voltage of the output signal to the input stage for the dc offset cancellation. The input stage comprises a resistor network coupled between a pair of input nodes and a power line and comprising a common resistor, a pair of load resistors and a shunt resistor. The load resistors share a common terminal connected to the common resistor that is connected to the power line. The shunt resistor has two terminals respectively connected to the load resistors.

Isoxazole based neuronal nicotinic receptor ligands and methods of use

The invention relates to isoxazole derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.

NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF

The invention relates to aza-cyclic-indole-2-carboxamide derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.

Diagnosis and treatment of psoriatic arthritis

Methods and kits for diagnosing or predicting the risk of developing psoriatic arthritis in a subject in need of such diagnosis or risk prediction are provided, comprising measuring the expression level of one or more miRNAs disclosed herein in the sample of the subject, and compared the expression level of at least one of the miRNAs in the test sample with that of the psoriatic arthritis-free sample. Also provided are methods of treating psoriatic arthritis by reducing the expression level of at least one of the miRNAs disclosed herein.

Amides useful for treating pain

The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R₆, R₇ and R₈ are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.

ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF

The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.

DRIVING SYSTEM FOR DRIVING A SCAN-TYPE DISPLAY

A driving system includes a scan driving device. The scan driving device includes a configuration register, a counter, multiple comparators and a driver. The configuration register generates a counting parameter and multiple scan order parameters based on a serial input signal and a clock signal. The counter generates a counting value based on the clock signal, an enable signal and the counting parameter. Each comparator compares the counting value with a respective one of the scan order parameters to generate a comparison result. The driver generates multiple scan driving signals for driving a scan-type display based on the clock signal, on the enable signal and on the comparison results respectively generated by the comparators.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) 2. The compound according to wherein{'sub': 1', 'b, 'Yis —N(R)—;'}{'sub': '2', 'Yis O; and'}{'sub': 3', 'c, 'Yis —N(R)—.'}3. The compound according to claim 2 , wherein Lis cycloalkyl wherein the cycloalkyl is cyclopentyl or cyclohexyl.4. The compound of claim 3 , wherein Aris phenyl.5. The compound according to claim 4 , wherein the phenyl is unsubstituted or substituted with 1 claim 4 , 2 claim 4 , 3 claim 4 , 4 claim 4 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 4 , alkyl claim 4 , arylalkyl claim 4 , halogen claim 4 , haloalkyl claim 4 , or RRN— wherein Rand Rare each independently hydrogen claim 4 , alkyl claim 4 , or haloalkyl.6. The compound according to claim 5 , wherein{'sub': '1', 'Ris hydroxy; and'}{'sub': 2', '3', '4', '5, 'R, R, R, and Rare hydrogen.'}7. The compound according to claim 2 , wherein Lis a bond.8. The compound according to claim 7 , wherein Aris a monocyclic heterocycle fused to a phenyl.9. The compound of claim 8 , wherein{'sub': '1', 'Ris hydroxy;'}{'sub': '2', 'Ris hydrogen, and'}{'sub': '1', 'Aris 3,4-dihydro-2H-chromen-3-yl.'}10. The compound according to wherein Aris optionally substituted with 1 claim 9 , 2 claim 9 , 3 claim 9 , 4 claim 9 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 9 , alkyl claim 9 , arylalkyl claim 9 , halogen claim 9 , haloalkyl claim 9 , or RRN— wherein Rand Rare each independently hydrogen claim 9 , alkyl claim 9 , or haloalkyl.11. The compound according to claim 8 , wherein{'sub': '1', 'Ris hydroxy;'}{'sub': '2', 'Ris hydrogen; and'}{'sub': '1', 'Aris 3,4-dihydro-2H-chromen-4-yl.'}12. The compound according to wherein Aris optionally substituted with 1 claim 11 , 2 claim 11 , 3 claim 11 , 4 claim 11 , or 5 substituents as represented by Rand each Ris independently alkoxy claim 11 , alkyl claim 11 , arylalkyl claim 11 , halogen claim 11 , ...

Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X 1 -X 5 , R 5 -R 8b , Z 1 -Z 2 and Ar 1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

RADIO-FREQUENCY FRONT-END SUPPORTING MULTIPLE WIRELESS COMMUNICATION STANDARDS

A radio-frequency (RF) front-end supporting at least a first and second wireless communication bands includes a mixer arranged for mixing a received signal with a first local oscillation signal when the shared receiver front-end performs the reception operation according to the first wireless communication band, and for mixing the received signal with a second local oscillation signal when the shared receiver front-end performs the reception operation according to the second wireless communication band, wherein the first and second local oscillation signals are different in frequency. 1. A radio-frequency (RF) front-end supporting at least a first and second wireless communication bands , comprising: 'a mixer, for mixing a received signal with a first local oscillation signal when the shared receiver front-end performs the reception operation via the first wireless communication band, and mixing the received signal with a second local oscillation signal when the shared receiver front-end performs the reception operation via the second wireless communication band, wherein the first and second local oscillation signals are different in frequency.', 'a shared receiver front-end comprising2. The RF front-end of claim 1 , wherein the first and second wireless communication bands are included in specified spectrums defined by at least one of a first and second wireless communication standards.3. The RF front-end of claim 2 , wherein the RF front-end is operative for a time division duplexing (TDD) scheme.4. The RF front-end of claim 3 , further comprising:a first transmitter front-end arranged for performing a transmission operation according to the first wireless communication standard; anda second transmitter front-end arranged for performing a transmission operation according to the second wireless communication standard;wherein during each time slot of the TDD scheme, only one of the first transmitter front-end, the second transmitter front-end and the shared receiver ...

NEURONAL NICOTINIC AGONISTS AND METHODS OF CORRELATING COMT SNPS

This application is directed to a-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein. 1. A method of identifying a patient with schizophrenia as a candidate for effective treatment with a nicotinic acetylcholine receptor ligand modulator , the method comprising:(a) obtaining a sample from the patient with schizophrenia;(b) determining the identity of an allele of at least one single nucleotide polymorphism (SNP) locus associated with the catechol-O-methyltransferase (COMT) gene in the sample;(c) determining the smoking status of the patient with schizophrenia;(d) identifying the patient with schizophrenia as a candidate for effective treatment with the nicotinic alpha 7 receptor agonist based on the presence or absence of a particular SNP allele associated with the COMT gene in the sample and the smoking status of the patient with schizophrenia; and(e) administering to the patient in need thereof an effective amount of a particular nicotinic acetylcholine receptor ligand modulator based upon result of step (d).2. The method of claim 1 , wherein the nicotinic acetylcholine receptor is α-7 nicotinic receptor.3. A method of identifying a patient with schizophrenia with an increased likelihood of response to treatment with a nicotinic alpha 7 receptor agonist claim 1 , the method comprising:(a) obtaining a sample from the patient with schizophrenia;(b) determining the identity of an allele of at least one single nucleotide polymorphism (SNP) locus associated with the catechol-O-methyltransferase (COMT) gene in the sample;(c) determining the smoking status of the patient with schizophrenia; and(d) identifying the patient with schizophrenia as having an increased ...

PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE

The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture. 1. A composition , comprising:(i) a nicotinic acetylcholine receptor ligand and(ii) a nicotinic acetylcholine receptor subtype α4β2 positive allosteric modulator in admixture with at least one pharmaceutically acceptable excipient.2. The composition of claim 1 , wherein the nicotinic acetylcholine receptor ligand is a nicotinic acetylcholine receptor subtype α4β2 ligand demonstrating a Kvalue that as measured by [H]-cytisine binding assay (KCyt) of about 0.001 nanomolar to about 100 micromolar.3. The composition of claim 1 , wherein the nicotinic acetylcholine receptor ligand is a nicotinic acetylcholine receptor subtype α4β2 agonist or partial agonist.4. The composition of claim 1 , wherein the nicotinic acetylcholine receptor ligand is a heterocyclic ether derivative claim 1 , a N-substituted diazabicyclic derivative claim 1 , or a heterocyclic substituted amino azacycle compound.5. The composition of claim 1 , wherein the nicotinic acetylcholine receptor ligand is a compound selected from:5-[(2R)-azetidin-2-ylmethoxy]-2-chloropyridine,(3R)-1-pyridin-3-ylpyrrolidin-3-amine, and2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine;3-(5,6-dichloro-pyridin-3-yl)-1(S),5(S)-3,6-diazabicyclo[3.2.0]heptane; and(R,R)-1-(pyridin-3-yl)octahydro-pyrrolo[3,4-b]pyrrole;or is a pharmaceutically acceptable salt thereof.6. The composition of claim 1 , wherein the nicotinic acetylcholine receptor ligand is selected from aryl-fused azapolycyclic compounds claim 1 , aryl-substituted olefinic amine compounds claim 1 , pyridopyranoazepine derivatives claim 1 , benzylidene- and cinnamylidene-anabaseines claim 1 , and 3-pyridoxylalkyl heterocyclic ether compounds.7. The compound of claim 6 , wherein the nicotinic acetylcholine receptor ligand is selected from the group consisting of:5-[(2R)-azetidin-2 ...

INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) 127.-. (canceled)28. A compound , or a pharmaceutically acceptable salt thereof , selected from the group consisting of:2,11-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[b]indole;5-[6-(4-iodophenyl)pyridazin-3-yl]-2,11-dimethyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[b]indole;9-methyl-6-[2-(6-methylpyridin-3-yl)ethyl]-3,4,5,6-tetrahydro-1H-2,5-methanoazepino[4,3-b]indole;2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-1,4-methanopyrido[4,3-b]indole;6,10-dimethyl-9-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,9-tetrahydro-1H-4,1-(epiminomethano)carbazole;2,6-dimethyl-9-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,9-tetrahydro-1H-1,4-methano-3-carboline;6,11-dimethyl-9-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,9-tetrahydro-1H-1,4-(epiminomethano)carbazole;2,11-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-5,6,7,8,9,10-hexahydro-6,9-epiminocyclohepta[b]indole;2,12-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole;6,10-dimethyl-9-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,9-tetrahydro-1H-1,4-epiminocarbazole;2,9-dimethyl-6-[2-(6-methylpyridin-3-yl)ethyl]-1,2,3,4,5,6-hexahydro-1,5-methanoazepino[4,3-b]indole;2,9-dimethyl-6-[2-(6-methylpyridin-3-yl)ethyl]-1,2,3,4,5,6-hexahydro-1,4-methanoazepino[4,3-b]indole;2,11-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-5,6,7,8,9,10-hexahydro-6,10-epiminocyclohepta[b]indole;(5aS*,7S*,10R*,10aR*)-2,11-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-5,5a,6,7,8,9,10,10a-octahydro-7,10-epiminocyclohepta[b]indole;(5aR*,7S*,10R*,10aS*)-2,11-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-5,5a,6,7,8,9,10,10a-octahydro-7,10-epiminocyclohepta[b]indole;(5aS*,7S*,11R*,11aR*)-2,12-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-5a,6,7,8,9,10,11,11a-octahydro-5H-7,11-epiminocycloocta[b]indole;(5aR*,7S*,11R*,11aS*)-2,12-dimethyl-5-[2-(6-methylpyridin-3-yl) ...

DIAGNOSIS AND TREATMENT OF PSORIATIC ARTHRITIS

Methods and kits for diagnosing or predicting the risk of developing psoriatic arthritis in a subject in need of such diagnosis or risk prediction are provided, comprising measuring the expression level of one or more miRNAs disclosed herein in the sample of the subject, and compared the expression level of at least one of the miRNAs in the test sample with that of the psoriatic arthritis-free sample. Also provided are methods of treating psoriatic arthritis by reducing the expression level of at least one of the miRNAs disclosed herein. 1. An in vitro method for detecting or predicting the risk of developing psoriatic arthritis in a subject , comprising the step of measuring the expression level of at least one miRNA selected from the group consisting of miR-146a-5p and miR-941 in the test sample of the subject , where in a higher expression level of at least one miRNA in the test sample , relative to the expression level of at least one corresponding miRNA in a psoriatic arthritis-free sample , is indicative of the subject having psoriatic arthritis or has a risk of developing psoriatic arthritis.2. The method of claim 1 , wherein the miRNA expression level is determined by real-time PCR.3. The method of claim 1 , wherein the miRNA expression level is determined by an oligonucleotide probe at least 90% identical to SEQ ID NO: 1 or SEQ ID NO:2.4. The method of claim 1 , wherein the sample is CD14+ monocyte.5. The method of claim 1 , wherein the sample is osteoclast.6. The method of claim 5 , wherein the osteoclast is derived from CD14+ monocyte.7. A method for treating psoriatic arthritis in a subject claim 5 , comprising the step of administering a miR-146a-5p inhibitor at least 90% identical to SEQ ID NO: 1 or a miR-941 inhibitor at least 90% identical to SEQ ID NO:2.8. The method of claim 7 , wherein the miR-146a-5p inhibitor is SEQ ID NO:5.9. The method of claim 7 , wherein the miR-941 inhibitor is SEQ ID NO:4.10. A method for determining the efficacy of a ...

APPARATUSES AND METHODS FOR PROVIDING MULTI-STANDBY MODE OF WIRELESS COMMUNICATIONS USING SINGLE SUBSCRIBER IDENTITY CARD WITH MULTIPLE SUBSCRIBER NUMBERS

A communication device is provided with a processing unit. The processing unit reads a plurality of elementary files from a single subscriber identity card for each of a plurality of subscriber numbers when power-on, and registers to a network for each of the subscriber numbers according to the read elementary files. Also, the processing unit enables a multi-standby mode of wireless communications in response to successful registration to the network for at least two of the subscriber numbers. 1. A communication device , comprising:a processing unit configured to read a plurality of elementary files from a single subscriber identity card for each of a plurality of subscriber numbers when power-on, configured to register to a network for each of the subscriber numbers according to the read elementary files, and configured to enable a multi-standby mode of wireless communications in response to successful registration to the network for at least two of the subscriber numbers.2. The communication device of claim 1 , further comprising a storage unit configured to store the read elementary files.3. The communication device of claim 1 , wherein claim 1 , when at least one of the read elementary files is updated during the registration to the network claim 1 , the processing unit further writes the at least one updated elementary file back to the subscriber identity card.4. The communication device of claim 1 , wherein the processing unit further:activates one subscriber identity module (SIM) instance in the subscriber identity card at a time for each of the subscriber numbers; andreads the elementary files of the activated SIM instance.5. The communication device of claim 4 , wherein the processing unit further:issues a first command to the subscriber identity card for activating the SIM instance;receives a response code corresponding to the first command from the subscriber identity card, wherein the response code indicates the communication device to fetch a proactive ...

APPARATUSES AND METHODS FOR PROVIDING MULTI-STANDBY MODE OF WIRELESS COMMUNICATIONS USING SINGLE SUBSCRIBER IDENTITY CARD WITH MULTIPLE SUBSCRIBER NUMBERS

A communication device is provided with a processing unit. The processing unit determines whether at least one elementary file in a single subscriber identity card is required to be read out. If so, the processing unit activates one subscriber identity module instance in the subscriber identity card for the elementary file, and reads the elementary file from the subscriber identity card. 1. A communication device , comprising:a processing unit configured to determine whether at least one elementary file in a single subscriber identity card is required to be read out, and if so, configured to activate one subscriber identity module (SIM) instance in the subscriber identity card for the elementary file, and configured to read the elementary file from the subscriber identity card.2. The communication device of claim 1 , further comprising a storage unit for storing the read elementary file3. The communication device of claim 2 , wherein the processing unit further determines whether the read elementary file is updated claim 2 , if so claim 2 , updates the read elementary file stored in the storage unit claim 2 , and writes the updated elementary file back to the subscriber identity card in response to a trigger event indicating one of the following:completion of a detachment procedure; andpower-off of the communication device.4. The communication device of claim 1 , wherein the processing unit further determines whether the read elementary file is updated claim 1 , and if so claim 1 , writes the updated elementary file back to the subscriber identity card.5. A method for accessing data in a single subscriber identity card claim 1 , executed by a micro-processing unit (MPU) of a Baseband chip claim 1 , comprising:determining whether at least one elementary file in the subscriber identity card is required to be read out; and activating one subscriber identity module (SIM) instance in the subscriber identity card for the elementary file; and', 'reading the elementary file ...

COMPOSITE FILM AND MANUFACTURING METHOD FOR THE SAME AND BATTERY COMPRISING COMPOSITE FILM

A composite film, a manufacturing method for the same, and a battery comprising the composite film are provided. The composite film includes a first layer and a second layer on a side of the first layer. The first layer includes a first polyolefin. The first polyolefin has an orientation function of at least 0.6. The first polyolefin has a repeating unit of 2. The composite film according to claim 1 , wherein a melting temperature (Tm) of the first polyolefin differs with a melting temperature of the second polyolefin by at least 55° C.3. The composite film according to claim 1 , wherein the first polyolefin has a melting temperature within a range of 220 to 240° C. claim 1 , and the second polyolefin has a melting temperature within a range of 130 to 165° C.4. The composite film according to claim 1 , wherein the first polyolefin has a melting flow index of 4 g/10 min to 30 g/10 min claim 1 , the second polyolefin has a melting flow index of 0.2 g/10 min to 6 g/10 min.5. The composite film according to claim 1 , wherein the orientation function of the first polyolefin is 0.6 to 0.95.6. The composite film according to claim 5 , wherein a melting temperature of the first polyolefin differs with a melting temperature of the second polyolefin by at least 55° C.7. The composite film according to claim 5 , wherein the first polyolefin has a melting temperature within a range of 220 to 240° C. claim 5 , and the second polyolefin has a melting temperature within a range of 130 to 165° C.8. The composite film according to claim 5 , wherein the first polyolefin has a melting flow index of 4 g/10 min to 30 g/10 min claim 5 , and the second polyolefin has a melting flow index of 0.2 g/10 min to 6 g/10 min.9. The composite film according to claim 1 , wherein the first layer is formed of a material selected from polymethylpentene claim 1 , polybutene claim 1 , and a combination thereof claim 1 , and the second layer is formed of a material selected from polyethylene claim 1 , ...

DIAGNOSIS AND TREATMENT OF PSORIATIC ARTHRITIS

Methods and kits for diagnosing or predicting the risk of developing psoriatic arthritis in a subject in need of such diagnosis or risk prediction are provided, comprising measuring the expression level of one or more miRNAs disclosed herein in the sample of the subject, and compared the expression level of at least one of the miRNAs in the test sample with that of the psoriatic arthritis-free sample. Also provided are methods of treating psoriatic arthritis by reducing the expression level of at least one of the miRNAs disclosed herein. 1. A method for detecting or predicting the risk of developing psoriatic arthritis and treating psoriatic arthritis in a subject in need thereof , comprising the step of(a) obtaining a test sample from the subject, wherein the subject exhibits one or more symptoms of psoriatic arthritis or is at risk of developing psoriatic arthritis;(b) measuring the expression level of miR-146a-5p in the test sample of the subject;(c) identifying the subject as having psoriatic arthritis or has a risk of developing psoriatic arthritis if the expression level of at least one miRNA in the test sample in step (b) is higher relative to the expression level of at least one corresponding miRNA in a psoriatic arthritis-free sample;(d) administering to the subject a therapeutic agent to treat psoriatic arthritis.2. The method of claim 1 , wherein the miRNA expression level is determined by real-time PCR.3. The method of claim 1 , wherein the miRNA expression level is determined by an oligonucleotide probe at least 90% complimentary to SEQ ID NO: 1.4. The method of claim 1 , further comprising measuring the expression level of miR-miR-941 in the test sample of the subject.5. The method of claim 4 , wherein the miRNA expression level is determined by real-time PCR.6. The method of claim 4 , wherein the miRNA expression level is determined by an oligonucleotide probe at least 90% complimentary to SEQ ID NO: 2.7. The method of claim 1 , wherein the sample is ...

TERTIARY AMIDES AND METHOD OF USE

Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G, G, G, L, L, and Lare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions. 5. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '2', 'sub': 1', '3', '1', '3', '1', '3', '1', '3, 'Gis phenyl; wherein the phenyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from C-Calkoxy, C-Calkyl, or halogen, wherein the C-Calkyl and C-Calkoxy are unsubstituted or optionally substituted with one, two, or three fluorines.'}6. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '2', 'sub': 1', '3', '1', '3, 'Gis selected from the group consisting of 2-furanyl and 2-thiophenyl; wherein the 2-furanyl and 2-thiophenyl are unsubstituted or optionally substituted with 1 or 2 substituents independently selected from halogen or C-Calkyl, wherein the C-Calkyl is unsubstituted or optionally substituted with one, two, or three fluorines.'}7. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '3', 'sub': '2', 'Gis —COH.'}8. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '3', 'sub': 2', '1', '6', '3, 'Gis selected from the group consisting of —P(O)(OH), —P(O)(OH)(OC-Calkyl), and —P(O)(CH)(OH).'}9. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '3', 'sub': 2', '3', '3, 'Gis selected from the group consisting of —B(OH), —SOH, —CH(OH)CF, —C(O)NH(OH), and —C(O)NH(CN).'}10. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': 3', 'G3a', 'G3a', 'G3a', 'G3a', 'G3a', 'G3a', ' ...

METHOD FOR ENHANCING PERFORMANCE OF A COMMUNICATIONS APPARATUS IN A PLMN SEARCH PROCEDURE AND A COMMUNICATIONS APPARATUS UTILIZING THE SAME

A communications apparatus includes a radio transceiver, a memory device and a processor. The radio transceiver transmits or receives wireless radio frequency signals to or from an air interface. The memory device stores a registration database including one or more sets of registration data. Each set of registration data corresponds to an International Mobile Subscriber Identity (IMSI). The processor determines whether performing a PLMN search procedure is required, and when performing a PLMN search procedure is required, the processor retrieves suitable registration data from the registration database according to a currently used IMSI and performs the PLMN search procedure via the radio transceiver based on the retrieved suitable registration data. 1. A communications apparatus , comprising:a radio transceiver, capable of transmitting or receiving wireless radio frequency signals to or from an air interface;a memory device, storing a registration database comprising one or more sets of registration data, wherein each set of registration data corresponds to an International Mobile Subscriber Identity (IMSI); anda processor, determining whether performing a PLMN search procedure is required, and when performing a PLMN search procedure is required, retrieving suitable registration data from the registration database according to a currently used IMSI and performing the PLMN search procedure via the radio transceiver based on the retrieved suitable registration data.2. The communications apparatus as claimed in claim 1 , wherein the set of registration data comprises a PLMN ID of a registered PLMN.3. The communications apparatus as claimed in claim 2 , wherein the set of registration data further comprises a location area code (LAC) corresponding to the registered PLMN claim 2 , a routing area code (RAC) corresponding to the registered PLMN claim 2 , a tracking area code (TAC) corresponding to the registered PLMN claim 2 , a cell ID of a camped-on cell claim 2 , ...

Diplexer and Transceiver thereof

A diplexer, for coupling a first radio frequency (RF) signal corresponding to a first carrier frequency and a second RF signal corresponding to a second carrier frequency is disclosed. The diplexer includes a first port arranged to couple the first RF signal; a second port arranged to couple the second RF signal; a third port capable of connecting an antenna; a first impedance unit coupled to the first port and the third port; and a second impedance unit coupled to the second port and the third port; wherein the first port, the second port and the third port are coupled to a direct current (DC) ground; wherein the first impedance unit is arranged to provide an first open-circuit impedance against the second RF signal, and the second impedance unit is arranged to provide a second open-circuit impedance against the first RF signal. 1. A diplexer , for coupling a first radio frequency (RF) signal corresponding to a first carrier frequency and a second RF signal corresponding to a second carrier frequency , the diplexer comprising:a first port arranged to couple the first RF signal;a second port arranged to couple the second RF signal;a third port capable of connecting an antenna;a first impedance unit coupled to the first port and the third port; anda second impedance unit coupled to the second port and the third port;wherein the first port, the second port and the third port are coupled to a direct current (DC) ground;wherein the first impedance unit is arranged to provide an first open-circuit impedance against the second RF signal, and the second impedance unit is arranged to provide a second open-circuit impedance against the first RF signal.2. The diplexer of claim 1 , wherein each of the first port claim 1 , the second port and the third port is coupled to the DC ground via at least one inductor of one of the first impedance unit and the second impedance unit.3. The diplexer of claim 1 , wherein the diplexer is arranged to provide the first RF signal and the ...

Energy Acquisition and Power Supply System

An energy acquisition and power supply system is provided. The power supply system includes a plurality of power elements, each of the power elements including a transistor capable of conduction path switching, a current regulator having a dynamic substrate selection circuit and a reverse leakage current suppression circuit as well as a voltage regulator, wherein the dynamic substrate selection circuit selects a substrate potential of the transistor capable of conduction path switching dynamically to reduce a substrate leakage current of the transistor capable of conduction path switching, and the reverse leakage current suppression circuit is utilized for switching the power element at a local end to reduce transient reverse leakage current and current consumption of the power element at the local end for an input voltage, such that an output current for the power element at the local end is maximized. 1. An energy acquisition and power supply system , including:a rectification unit for rectifying an input energy to a DC voltage lower than the input in order to perform a power supply process for a back end circuit, the rectification unit including:a plurality of power elements for rectifying a voltage to a DC voltage by switching a conduction path for the input energy, each of the power elements including a transistor capable of conduction path switching, a current regulator having a dynamic substrate selection circuit and a reverse leakage current suppression circuit as well as a voltage regulator having an adaptive voltage control circuit, wherein the dynamic substrate selection circuit selects a substrate potential of the transistor capable of conduction path switching dynamically to reduce a substrate leakage current of the transistor capable of conduction path switching, and the reverse leakage current suppression circuit is utilized for switching the power element at a local end to reduce transient reverse leakage current and current consumption of the power ...

SELECTIVE LASER SINTERING COMPOSITION AND SELECTIVE LASER SINTERING 3D PRINTING METHOD EMPLOYING THE SAME

A selective laser sintering composition and a selective laser sintering 3D printing method employing the same are provided. The selective laser sintering composition includes a nanoscale inorganic powder and a thermoplastic vulcanizate powder. The temperature difference (ΔT) between the onset temperature for melting the thermoplastic vulcanizate powder and the onset temperature at which the thermoplastic crystallizes vulcanizate powder is greater than or equal to 10° C. The thermoplastic vulcanizate powder includes a thermoplastic and a crosslinked polymer. The temperature difference (ΔT) between the onset temperature for melting the thermoplastic and the onset temperature at which the thermoplastic crystallizes is greater than or equal to 10° C. , and the weight ratio of the thermoplastic to the crosslinked polymer is from 1:1 to 1:4. 1. A selective laser sintering composition , comprising:a nanoscale inorganic powder having a particle size distribution D90 of 1 nm to 950 nm; and{'b': 82', '82, 'a thermoplastic vulcanizate powder, wherein the temperature difference (ΔT) between the onset temperature for melting the thermoplastic vulcanizate powder and the onset temperature at which the thermoplastic crystallizes vulcanizate powder is greater than or equal to 10° C., and the thermoplastic vulcanizate powder has a particle size distribution D90 of 40 m to 100 m,'}wherein the thermoplastic vulcanizate powder includes:a thermoplastic, wherein the temperature difference (ΔT) between the onset temperature for melting the thermoplastic and the onset temperature at which the thermoplastic crystallizes is greater than or equal to 10° C.; anda crosslinked polymer, wherein the crosslinked polymer is a crosslinked rubber, a crosslinked thermoplastic elastomer, or a combination thereof, and wherein the thermoplastic and the crosslinked polymer have a weight ratio of 1:1 to 1:4.2. The selective laser sintering composition as claimed in claim 1 , wherein the nanoscale inorganic ...

PACKAGE STRUCTURE

A package structure includes a first substrate, a second substrate, a plurality of dies, a plurality of first conductive elements, and a plurality of second conductive elements. The first substrate has a recessed region. The second substrate is disposed in the recessed region and protrudes from the first substrate. The dies are disposed on the first substrate and the second substrate, such that the second substrate is disposed between the first substrate and the dies. The first conductive elements are disposed between the dies and the first substrate. The dies are electrically connected with the first substrate through the first conductive elements. The second conductive elements are disposed between the dies and the second substrate. The dies are electrically connected with the second substrate through the second conductive elements. 1. A package structure , comprising:a first substrate;a plurality of dies disposed on the first substrate, wherein the dies are adjacent to each other and collectively have a recessed region;a second substrate disposed in the recessed region and electrically connected to the dies, wherein a surface of the second substrate facing away from the recessed region is substantially flush with surfaces of the dies facing away from the first substrate; anda plurality of first conductive elements disposed between the dies and the first substrate, wherein the dies are electrically connected to the first substrate through the first conductive elements.2. The package structure of claim 1 , wherein each of the dies has a circuit structure and a conductive via electrically connected to the circuit structure therein claim 1 , and the package structure further comprises:a plurality of second conductive elements disposed between the dies and the second substrate, wherein the second substrate is electrically connected to the first substrate through the second conductive elements, the conductive via, the circuit structure and the first conductive elements ...

METHOD OF SELECTING AN ACTIVE SIM FOR AN EMERGENCY SERVICE AND MULTI-SIM DEVICE UTILIZING THE SAME

A method of selecting an active SIM for an emergency service and a multi-SIM device utilizing the same are disclosed. The method, adopted by the multi-SIM device, includes: receiving a request for an emergency call on a first SIM camping on an LTE network; determining whether a second SIM camps on a second communications network which supports an emergency service; and when the second communications network supports the emergency service, performing the emergency call from the second SIM. 1. A method , adopted by a multi-SIM device supporting a plurality of SIMs , the method comprising:receiving a request for an emergency call on a first SIM camping on an LTE network;determining whether a second SIM camps on a second communications network which supports an emergency service; andwhen the second communications network supports the emergency service, performing the emergency call from the second SIM.2. The method of claim 1 , further comprising:determining whether the first SIM camping on the LTE network which supports the emergency service;wherein the step of determining whether the second SIM camps on the second communications network which supports the emergency service comprises:when the LTE network does not support the emergency service, determining whether the second SIM camps on the second communications network which supports the emergency service.3. The method of claim 2 , wherein the step of determining whether the first SIM camping on the LTE network which supports the emergency service comprises:determining whether the LTE network supports Voice over LTE (VoLTE) or IP Multimedia Subsystem (IMS).4. The method of claim 1 , further comprising:determining whether the first SIM camping on the LTE network which has coverage;wherein the step of determining whether the second SIM camps on the second communications network which supports the emergency service comprises:when the LTE network has no coverage, determining whether the second SIM camps on the second ...

PACKAGE STRUCTURE

A package structure includes a first substrate, a second substrate, a plurality of dies, a plurality of first conductive elements, and a plurality of second conductive elements. The first substrate has a recessed region. The second substrate is disposed in the recessed region and protrudes from the first substrate. The dies are disposed on the first substrate and the second substrate, such that the second substrate is disposed between the first substrate and the dies. The first conductive elements are disposed between the dies and the first substrate. The dies are electrically connected with the first substrate through the first conductive elements. The second conductive elements are disposed between the dies and the second substrate. The dies are electrically connected with the second substrate through the second conductive elements. 1. A package structure , comprising:a first substrate having a recessed region;a second substrate disposed in the recessed region and protruding from the first substrate;a plurality of dies disposed on the first substrate and the second substrate, such that the second substrate is disposed between the first substrate and the dies;a plurality of first conductive elements disposed between the dies and the first substrate, wherein the dies are electrically connected to the first substrate through the first conductive elements;a plurality of second conductive elements disposed between the dies and the second substrate, wherein the dies are electrically connected to the second substrate through the second conductive elements;a first solder mask layer at least disposed on the first substrate in the recessed region; anda second solder mask layer at least disposed on a surface of the second substrate facing the recessed region.2. The package structure of claim 1 , wherein a height of the first conductive elements is greater than a height of the second conductive elements.3. (canceled)4. The package structure of claim 1 , wherein the first ...

METHOD OF SELECTING A SIM FOR A LOCATION SERVICE AND MULTI-SIM DEVICE UTILIZING THE SAME

A method of selecting a SIM for a location service and a multi-SIM device utilizing the same are disclosed. The method, adopted by a multi-SIM device, includes: acquiring Secure User Plane Location (SUPL) information from a corresponding communications network which each SIM is in connection with; determining which communications network supports a location service based on the SUPL information; and requesting the location service on a SIM that is in connection with the supported communications network. 1. A method , adopted by a multi-SIM device , comprising:acquiring Secure User Plane Location (SUPL) information from a corresponding communications network which each SIM is in connection with;determining which communications network supports a location service based on the SUPL information; andrequesting the location service on a SIM that is in connection with the supported communications network.2. The method of claim 1 , wherein the step of the requesting the location service comprises:establishing a priority list which prioritizes SIMs connecting to the corresponding communications networks that support the location service;selecting the SIM from the priority list according to a priority thereof; andrequesting the location service on the selected SIM.3. The method of claim 2 , wherein the step of the establishing the priority list comprises:establishing the priority list according to the SUPL information.4. The method of claim 2 , wherein the step of the establishing the priority list comprises:establishing the priority list according to data rates of the communications networks which support the location service.5. The method of claim 2 , further comprising:removing a first SIM from the priority list after the multi-SIM device fails to acquire the location service on the first SIM.6. The method of claim 2 , wherein the step of the selecting the SIM from the priority list comprises:when no SIM is on the priority list, determining whether a SUPL version fallback ...

INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) 2. The compound according to of formula (I) claim 1 , whereina is a double bond;{'sup': 1', '2', '3', '4', '1', '1a, 'R, R, R, and Rare each independently hydrogen, alkyl, halogen, haloalkyl, G, or —OR;'}{'sup': 5', '1a', '1a', '2a, 'sub': '2', 'Ris hydrogen, alkyl, haloalkyl, C(O)OR, C(O)R, or S(O)R;'}{'sup': '6', 'X is NR;'}{'sup': 6', '2a', '1a', '4a', '5a', '1a', '4a', '5a', '1a', '4a', '5a', 'b', '3a', '4a', '5a', '1', '4a', '5a', '2', '1', '4a', '5a', '1', '1', '2', '1, 'sub': 2', 'm', 'm', 'm', 'm', 'm, 'claim-text': [{'sup': 4a', '5a, 'Rand Rare each hydrogen;'}, 'm is 1, 2, 3, or 4; and, 'Ris —S(O)R, —C(O)R, —(CRR)—OR, —(CRR)—C(O)OR, —(CRR)—C(O)N(R)(R), —(CRR)-G, —(CRR)-G-G, —CR═CR-G, -G, or -G-G;'}{'sup': 1', '1b', '1b', 'b', '3b', '1b', '2b', 'b', '3b', '1b', '1b', 'b', '3b', 'b', '3b', 'a', '1b', 'a', '1b', 'a', 'b', '3b', '4b', '5b', '4b', '5b', '1b', '4b', '5b', '1b', '4b', '5b', 'b', '3b', '4b', '5b', '1b', '4b', '5b', '2b', '4b', '5b', 'b', '3b', '4b', '5b', '1b', '4b', '5b', '1b', '4b', '5b', 'b', '3b', '4b', '5b', 'b', '3b', '4b', '5b', 'a', '1b', '4b', '5b', 'a', '1b', '4b', '5b', 'a', 'b', '3b, 'sub': 2', '2', '2', 'm', '2', 'm', 'm', 'm', 'm', 'm', '2', 'm', '2', 'm', 'm', 'm', 'm', 'm', 'm', 'm, 'Gis aryl, cycloalkyl, heteroaryl, or heterocycle unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, cyano, —NO, —OR, —OC(O)R, —OC(O)N(R)(R), —SR, —S(O)R, —S(O)N(R)(R), —C(O)R, —C(O)OR, —C(O)N(R)(R), —N(R)(R), —N(R)C(O)R, —N(R)C(O)O(R), —N(R)C(O)N(R)(R), —(CRR)—NO, —(CRR)—OR, —(CRR)—OC(O)R, —(CRR)—OC(O)N(R)(R), —(CRR)—SR, —(CRR)—S(O)R, —(CRR)—S(O)N(R)(R), —(CRR)—C(O)R, —(CRR)—C(O)OR, —(CRR)—C(O)N(R)(R), —(CRR)—N(R)(R), —(CRR)—N(R)C(O)R, —(CRR)—N(R)C(O)O(R), —(CRR)—N(R)C(O)N(R)(R), cyanoalkyl, and haloalkyl.'}3. The compound according to of formula (I) claim ...

COMPOSITE FILM, METHOD FOR FABRICATING THE SAME AND APPLICATIONS THEREOF

A composite film includes a fiber structure layer and a filling material layer. The fiber structure layer has a plurality of fibers and a first melting temperature. The filling material layer is disposed on the fiber structure layer and has a second melting temperature. At least one of the fibers extends into the filling material layer, and the first melting temperature is greater than the second melting temperature. Wherein the fiber structure layer includes a polymer selected from a group consisting of PI, polyurethanes (PU), polyamide, polybenzimidazole, polycarbonate, polyacrylonitrile, polyethyleneterephtalate, poly(vinylidenefluoride), poly(4-methylpentene) (TPX), and the arbitrary combinations thereof; the filling material layer includes polyolefin or polyester. 1. A composite film comprising:a fiber structure layer, having a plurality of fibers and a first melting temperature; anda filling material layer, disposed on the fiber structure layer and has a second melting temperature; wherein at least one of the fibers extends into the filling material layer; the first melting temperature is greater than the second melting temperature; the fiber structure layer comprises a polymer selected from a group consisting of polyimide, polyurethane, polyamide, polybenzimidazole, polycarbonate, polyacrylonitrile, polyethyleneterephtalate, poly(vinylidenefluoride), poly(4-methylpentene), and the arbitrary combinations thereof; and the filling material layer comprises polyolefin or polyester.2. The composite film according to claim 1 , wherein the first melting temperature ranges from 200° C. to 400° C.; and the second melting temperature ranges from 90° C. to 180° C.3. The composite film according to claim 1 , wherein the composite film has a first resistance value under an operation temperature lower than 100° C. and a second resistance value under an operation temperature greater than or equal to 100° C.; and the second resistance value is about 10times of the first ...

Indole and indoline derivatives and methods of use thereof

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R 1 , R 2 , R 3 , R 4 , R 5 , U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

AZA-bridged ring-fused indoles and indolines

The present application relates to indole and indoline derivatives of formula (I) wherein a, R 1 , R 2 , R 3 , h, i, j, m, n, L, Q, and X are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions.

Pharmaceutical compositions and their methods of use

The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an a4ss2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

DERIVATIVES OF SUBSTITUTED SUBSTITUTES WITH BIARILO AS MODULATORS OF THE ACTIVITY OF NICOTINIC ACETILCOLINE RECEPTORS

La invención se relaciona con derivados de alcanos azabiciclicos sustituidos con biarilo, composiciones que comprenden dichos compuestos y con métodos para tratar afecciones y trastornos usando dichos compuestos y dichas composiciones.

BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS

Separators utilized in lithium batteries

Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands

Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor

The present invention relates to compounds of formula (I), that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Bridgehead amine ring-fused indoles and indolines useful to treat neurodegenerative and neuropsychiatric disorders

The present application relates to indole and indoline derivatives of formula (I), formula (II), formula (III), or formula (IV) wherein a, R2, R3, h, k, m, n, L, Q, X, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and their medicaments for treating neurodegeneration and neuropsychiatric disorders.

Biaryl substituted diazabicycloalkane derivatives

The invention relates biaryl substituted diazabicycloalkanes of foraula (I), and more particularly bicycloheteroaryl substituted fused diazabicycloalkane derivatives, compositions comprising such compounds, and such compounds for use for treating or preventing conditions and disorders related to both <x7 and α4β2 nAChR activity Formula: (I).

Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof

The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.

ANTIGONISTS OF THE VANILLOID RECEIVER OF THE SUBTIPO (VR1) AND USES OF THE SAME

La presente invencion se refiere a compuestos de formula (i) donde las variables X1, X2,Y, R1a,R1b, R2a, R2b, A1, A2, A3 , y A4 son como se definen en la memoria descriptiva, y metodos de uso para tratar dolor, dolor neuropatico, alodinia, dolor asociado con inflamacion o una enfermedad inflamatoria, hiperalgesia inflamatoria, hiperactividad vesical, e incontinencia urinaria.

Indazole derivatives that inhibit trpv1 and uses thereof

Compounds of formula (I) wherein R3, R7, R9 and L are defined in the description are TRPV1 antagonists that exhibit low inhibitory activity against CYP3A4. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Amide derivatives as positive allosteric modulators and methods of use thereof

Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain

The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

Method of selecting an active SIM for an emergency service and multi-SIM device utilizing the same

A method of selecting an active SIM for an emergency service and a multi-SIM device utilizing the same are disclosed. The method, adopted by the multi-SIM device, includes: receiving a request for an emergency call on a first SIM camping on an LTE network; determining whether a second SIM camps on a second communications network which supports an emergency service; and when the second communications network supports the emergency service, performing the emergency call from the second SIM.

Antagonists of the trpv1 receptor and uses thereof

The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof

The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.

PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE

Una composicion que comprende un ligando de un receptor nicotinico neuronal y un modulador alosterico positivo de 4 2, un metodo para usarla y un articulo de manufactura relacionado.

Composite film and manufacturing method for the same and battery comprising composite film

A composite film, a manufacturing method for the same, and a battery comprising the composite film are provided. The composite film includes a first layer and a second layer on a side of the first layer. The first layer includes a first polyolefin. The first polyolefin has an orientation function of at least 0.6. The first polyolefin has a repeating unit of wherein R is an alkyl group having 2, 3, 4, or 5 carbon atoms. The second layer includes a second polyolefin. The second polyolefin has an orientation function of at least 0.5. The second polyolefin has a repeating unit of wherein A is a hydrogen or a methyl group.

Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof

The present invention is directed to compounds of formula (I), wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.

Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof

The present invention is directed to compounds of formula (I), wherein variables X, X, Y, R, R1, R, R, A, A, A, and A are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.

Amide derivatives as positive allosteric modulators and methods of use thereof

The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.

Method for estimating a risk for a subject suffering from atopic dermatitis, method for estimating an order of severity of atopic dermatitis for a subject suffering from, use of snp rs12313273 (c/t) as a biomarker for atopic dermatitis and use of snp rs1

6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine

Amide derivatives as positive allosteric modulators and methods of use thereof.

La presente invención se refiere a derivados de amida novedosos que son PAMs de los receptores nicotínicos neuronales, a composiciones que comprenden los mismos, a procesos para preparar dichos compuestos y a métodos para utilizar dichos compuestos y composiciones.

Indole and indoline derivatives and methods of use thereof

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein in a, R1-, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

6,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds

Indazole derivatives that inhibit trpv1 receptor

Compounds of formula (I), wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

Trpv1 antagonists.

En la presente solicitud se describen compuestos de la fórmula (I) o sales farmacéuticamente aceptables, solvatos, o combinaciones de los mismos, (I) en la cual X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, y "m" se definen en la descripción. También se describen composiciones que comprenden dichos compuestos y métodos para tratar condiciones y trastornos utilizando dichos compuestos y composiciones.

Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof

Compounds having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R1, R2 and R3 are as defined herein. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.

Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt or prodrug thereof (in which X1 - X5, R5 -R8b, Z1 - Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

A method for sharing network information and communication devices using the same

Kommunikationsvorrichtung (110) umfassend: einen Prozessor, der mit mindestens einer ersten Teilnehmeridentkarte (10, 20, 30, 40) und einer zweiten Teilnehmeridentkarte (10, 20, 30, 40) und mindestens einem Funksendeempfangsmodul (220) gekoppelt ist; wobei der Prozessor mindestens umfasst: eine erste Prozessorlogikeinheit, welche eingerichtet ist, einen Netzsuchvorgang für die erste Teilnehmeridentkarte (10, 20, 30, 40) über das Funksendeempfangsmodul (220) durchzuführen, um ein Netzsuchergebnis oder mehrere Netzsuchergebnisse zu erhalten; und eine zweite Prozessorlogikeinheit, welche eingerichtet ist, das Netzsuchergebnis bzw. die Netzsuchergebnisse unverzüglich nach dem Erhalt mit der zweiten Teilnehmeridentkarte (10, 20, 30, 40) zu teilen, sodass ein weiterer Netzsuchvorgang für die zweite Teilnehmeridentkarte (10, 20, 30, 40) vereinfacht oder übersprungen wird, dadurch gekennzeichnet, dass die erste Teilnehmeridentkarte (10, 20, 30, 40) und die zweite Teilnehmeridentkarte (10, 20, 30, 40) unterschiedlichen Zellsuchvorgängen oder PLMN-Suchvorgängen zugeordnet sind. A communication device (110) comprising: a processor coupled to at least a first subscriber identity card (10, 20, 30, 40) and a second subscriber identity card (10, 20, 30, 40) and at least one radio transceiver module (220); the processor comprising at least: a first processor logic unit configured to perform a network search operation on the first subscriber identity card (10, 20, 30, 40) via the radio transceiver module (220) to obtain a network search result or a plurality of network search results; and a second processor logic unit configured to share the network search result (s) immediately after receipt with the second subscriber identity card (10, 20, 30, 40) so that another network search operation for the second subscriber identity card (10, 20, 30, 40) is simplified or skipped, characterized in that the first subscriber identity card (10, 20, 30, 40) and the second subscriber identity card ...

Heterocyclic compounds and their methods of use

The invention relates to heterocyclic derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. The heterocyclic derivatives, more particularly can be substituted oxadiazole compounds and derivatives thereof.

Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof

Compounds having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R1, R2 and R3 are as defined herein. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.

Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

TRISUBSTITUTED-N - ((1S) -1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL) BENZAMIDES INHIBITING P2X3 AND P2X2 / 3 CONTAINING RECEPTORS

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors

A method for inhibiting adenosine kinase by administering a compound having formula (I) wherein R<1> and R<2> are independently selected from H, loweralkyl, C1-C6alkoxyC1-C6alkyl, arylC1-C6alkyl, -C(O)C1-C6alkyl, -C(O)aryl, -C(O)heterocyclic or may join together with the nitrogen to which they are attached to form a 5-7 membered ring optionally containing 1-2 additional heteroatoms selected from O, N or S; R<3> is selected from the group consisting of loweralkyl, loweralkenyl, loweralkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group, heteroarylalkyl or heterocycloalkyl wherein the heteroaryl and heterocyclic groups are linked directly or indirectly by a ring carbon; R<4> is selected from the group consisting of loweralkyl, loweralkenyl, loweralkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group heteroarylalkyl or heterocycloalkyl; and a dashed line --- indicates that a double bond is optionally present provided that proper valencies are maintained, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R<1>, R<2>, R<3> and R<4> are separately defined.

SUBTYPE 1 (VR1) VANILOID RECEPTOR ANTAGONISTS AND USES OF THESE

ANTAGONISTAS DO RECEPTOR VANILóIDE DE SUBTIPO 1 (VR1) E USOS DESTES. A presente invenção é dirigida a compostos da fórmula (1) em que variáveis X^ 1^, X^ 2^, Y, R^ 1a^, R^ 1b^, R^ 2a^, R^ 2b^, A~ 1~, A~ 2~, A~ 3~, e A~ 4~ são como definidas na descrição, e métodos de uso para tratar dor, dor neuropática, alodinia, dor associada com inflamação ou uma doença inflamatória, hiperalgesia inflamatória, hiperatividade da bexiga, e incontinência urinária. VANILOID RECEPTOR ANTAGONISTS, SUBTYPE 1 (VR1) AND USES OF THESE. The present invention is directed to compounds of formula (1) in which variables X ^ 1 ^, X ^ 2 ^, Y, R ^ 1a ^, R ^ 1b ^, R ^ 2a ^, R ^ 2b ^, A ~ 1 ~, A ~ 2 ~, A ~ 3 ~, and A ~ 4 ~ are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, hyperactivity of bladder, and urinary incontinence.

Rotating mechanism having buffering function

A rotating mechanism having a buffering function is disclosed to include a worm gear mounted in a holder block for rotating an antenna through a transmission rod and a rotating tube, a worm meshed with the worm gear, a pinion fastened to one end of the worm and rotatable by a motor, a pivot connector pivotally coupled between the worm and a part in the holder block and a spring member coupled between the pivot connector and the worm and defining therein a biasing space within which the worm is biasable relative to the pivot connector to avoid sticking, assuring smooth operation of the motor and stable supply of electric current to the motor

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Novel 1,2,4 oxadiazole compounds and methods of use thereof.

La invención se relaciona con compuestos de 1,2,4-oxadiazol y análogos de los mismos, representados por la fórmula (II), y composiciones y métodos de uso de los mismos.

Condensed Compounds That Inhibit Vanilla Receptor Subtype-1 (VR1)

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X<SUB>1</SUB>, X<SUB>2</SUB>, X<SUB>3</SUB>, X<SUB>4</SUB>, X<SUB>5</SUB>, R<SUB>5</SUB>, R<SUB>6</SUB>, R<SUB>7</SUB>, R<SUB>8a</SUB>, R<SUB>8b</SUB>, R<SUB>9</SUB>, Z<SUB>1</SUB>, Z<SUB>2 </SUB>and L are as defined in the description.

Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors

Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME

COMPUESTOS QUE SON DERIVADOS DE AZAADAMANTANO, PARTICULARMENTE DERIVADOS DE AZAADAMANTANO SUSTITUIDOS CON ÉTER O AMINA, Y SALES Y PRODROGAS DE ÉSTOS, COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS, MÉTODOS PARA USAR ESTOS COMPUESTOS Y COMPOSICIONES, PROCESOS PARA PREPARAR ESTOS COMPUESTOS, E INTERMEDIARIOS OBTENIDOS DURANTE ESTOS PROCESOS.